- Home
- GIPR vs ENSC Comparison
GIPR vs ENSC Comparison
Compare GIPR & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GIPR
- ENSC
- Stock Information
- Founded
- GIPR 2015
- ENSC 2003
- Country
- GIPR United States
- ENSC United States
- Employees
- GIPR N/A
- ENSC N/A
- Industry
- GIPR Real Estate Investment Trusts
- ENSC Biotechnology: Pharmaceutical Preparations
- Sector
- GIPR Real Estate
- ENSC Health Care
- Exchange
- GIPR Nasdaq
- ENSC Nasdaq
- Market Cap
- GIPR 7.7M
- ENSC 4.9M
- IPO Year
- GIPR 2021
- ENSC N/A
- Fundamental
- Price
- GIPR $1.48
- ENSC $2.16
- Analyst Decision
- GIPR
- ENSC
- Analyst Count
- GIPR 0
- ENSC 0
- Target Price
- GIPR N/A
- ENSC N/A
- AVG Volume (30 Days)
- GIPR 17.7K
- ENSC 60.9K
- Earning Date
- GIPR 08-14-2025
- ENSC 08-13-2025
- Dividend Yield
- GIPR N/A
- ENSC N/A
- EPS Growth
- GIPR N/A
- ENSC N/A
- EPS
- GIPR N/A
- ENSC N/A
- Revenue
- GIPR $9,711,058.00
- ENSC $6,224,081.00
- Revenue This Year
- GIPR N/A
- ENSC N/A
- Revenue Next Year
- GIPR N/A
- ENSC $1,381.48
- P/E Ratio
- GIPR N/A
- ENSC N/A
- Revenue Growth
- GIPR 11.25
- ENSC 256.35
- 52 Week Low
- GIPR $1.33
- ENSC $1.62
- 52 Week High
- GIPR $3.93
- ENSC $14.67
- Technical
- Relative Strength Index (RSI)
- GIPR 53.13
- ENSC 46.61
- Support Level
- GIPR $1.46
- ENSC $1.97
- Resistance Level
- GIPR $1.59
- ENSC $2.40
- Average True Range (ATR)
- GIPR 0.07
- ENSC 0.16
- MACD
- GIPR 0.01
- ENSC 0.00
- Stochastic Oscillator
- GIPR 68.99
- ENSC 44.19
About GIPR Generation Income Properties Inc.
Generation Income Properties Inc is an internally managed real estate investment company focused on acquiring and managing income-producing retail, office and industrial properties net leased to high-quality tenants in markets throughout the United States. Its key source of revenue is the rental income. The company holds properties in Alabama, Arizona, Colorado, the District of Columbia, Florida, Illinois, North Carolina and Virginia.
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.